Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients-Reference-Cited by-同舟云学术

Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients

Published:2018-04-05 Issue:5 Volume:20 Page:
ISSN:1523-3847
Container-title:Current Infectious Disease Reports
language:en
Short-container-title:Curr Infect Dis Rep

Author:

Heavner Mojdeh S.,Claeys Kimberly C.,Masich Anne M.,Gonzales Jeffrey P.

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Link

http://link.springer.com/article/10.1007/s11908-018-0614-0/fulltext.html

Reference102 articles.

1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.

2. Shortridge D, Pfaller MA, Castanheira M, Flamm RK. Antimicrobial activity of ceftolozane-tazobactam tested against enterobacteriaceae and pseudomonas aeruginosa with various resistance patterns isolated in US hospitals (2013–2016) as part of the surveillance program: program to assess ceftolozane-tazobactam susceptibility. Microb Drug Resist. 2017.

3. van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. Colistin vs. ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae. Clin Infect Dis. 2017.

4. Rodriguez-Avial I, Pena I, Picazo JJ, Rodriguez-Avial C, Culebras E. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing enterobacteriaceae strains. Int J Antimicrob Agents. 2015;46(6):616–21.

5. Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2017.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving the Safety of Clinical Management of COVID-19 Patients Receiving Aminoglycosides and Parenteral Nutrition: Y-site Compatibility Studies;Journal of Pharmaceutical Sciences;2023-10

2. Commentary: Population pharmacokinetics of colistin sulfate in critically ill patients: Exposure and clinical efficacy;Frontiers in Pharmacology;2022-09-09

3. Evaluating the usefulness of the estimated glomerular filtration rate for determination of imipenem dosage in critically ill patients;South African Medical Journal;2022-08-30

4. Optimal levofloxacin dosing regimens in critically ill patients with acute kidney injury receiving continuous renal replacement therapy;Journal of Critical Care;2021-06

5. Some Suggestions from PK/PD Principles to Contain Resistance in the Clinical Setting—Focus on ICU Patients and Gram-Negative Strains;Antibiotics;2020-10-06